1. Home
  2. SD vs ALLO Comparison

SD vs ALLO Comparison

Compare SD & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SandRidge Energy Inc.

SD

SandRidge Energy Inc.

HOLD

Current Price

$14.91

Market Cap

562.7M

Sector

Energy

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$2.23

Market Cap

539.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SD
ALLO
Founded
2006
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
562.7M
539.4M
IPO Year
2006
2018

Fundamental Metrics

Financial Performance
Metric
SD
ALLO
Price
$14.91
$2.23
Analyst Decision
Strong Sell
Strong Buy
Analyst Count
1
15
Target Price
$15.00
$8.35
AVG Volume (30 Days)
272.8K
10.5M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
3.07%
N/A
EPS Growth
12.43
34.09
EPS
0.50
N/A
Revenue
N/A
N/A
Revenue This Year
$12.65
N/A
Revenue Next Year
$1.75
$142,416.42
P/E Ratio
$29.74
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.52
$0.99
52 Week High
$18.45
$4.46

Technical Indicators

Market Signals
Indicator
SD
ALLO
Relative Strength Index (RSI) 45.68 45.93
Support Level $13.66 $2.12
Resistance Level $15.73 $2.71
Average True Range (ATR) 0.44 0.13
MACD 0.01 0.01
Stochastic Oscillator 33.99 43.55

Price Performance

Historical Comparison
SD
ALLO

About SD SandRidge Energy Inc.

SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. The company's primary areas of operation are the Mid-Continent in Oklahoma and Kansas.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: